TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HURA TuHURA Biosciences, Inc.

盘前交易 07-07 05:01:57 EDT

2.36

-0.08

-3.28%

最高2.50	最低2.34	成交量26.17万
今开2.44	昨收2.44	日振幅6.56%
总市值1.50亿	流通市值8,399万	总股本6,358万
成交额62.28万	换手率0.74%	流通股本3,559万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.36,"timestamp":1783368000000,"preClose":2.44,"halted":0,"volume":261700,"delay":0,"changeRate":-0.03278688524590167,"floatShares":35590700,"shares":63578528,"eps":-0.59396,"marketStatus":"盘前交易","change":-0.08,"latestTime":"07-07 05:01:57 EDT","open":2.44,"high":2.5,"low":2.34,"amount":622819.43745,"amplitude":0.065574,"askPrice":2.7,"askSize":50,"bidPrice":1.87,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.59396,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783431000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":2.36,"postHourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.36,"latestTime":"19:53 EDT","volume":1735,"amount":4125.5385,"timestamp":1783382022574,"change":-0.02,"changeRate":-0.008475,"amplitude":0.025424},"volumeRatio":0.19071713282304695},"requestUrl":"/m/hq/s/HURA","defaultTab":"news","newsList":[{"id":"1147397848","title":"TuHURA Biosciences提交新药临床试验申请，评估TBS-2025 VISTA抑制抗体在分子定义亚型AML及其他血液相关癌症中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1147397848","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147397848?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:50","pubTimestamp":1781524218,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences公司已提交一份新药临床试验申请，旨在评估其研发的TBS-2025 VISTA抑制抗体在分子定义亚型的急性髓系白血病及其他血液相关癌症中的疗效。TBS-2025作为一款靶向VISTA的抑制性抗体，其作用机制旨在调节肿瘤微环境，为那些现有疗法效果有限的AML及其他血液癌症患者提供新的潜在治疗选择。此次提交的申请将聚焦于通过分子特征定义的癌症亚组，体现了肿瘤学领域日益增长的个性化医疗趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136789265","title":"TuHURA生物科学公司与H.C. Wainwright & Co.达成市场发售协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1136789265","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136789265?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:35","pubTimestamp":1775680540,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司已与H.C. Wainwright & Co.正式签署市场发售协议，相关细节已通过美国证券交易委员会文件公开披露。该协议标志着公司在资本市场的战略布局取得新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195605532","title":"TuHURA生物科学公布2025年第四季度及全年财务业绩并发布公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1195605532","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195605532?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:46","pubTimestamp":1775044009,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司近日披露了其2025财年第四季度及全年的财务数据，同时向市场同步了企业最新动态。此次公告涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的阶段性成果。通过这份全面报告，投资者可清晰把握该公司在报告期内的运营状况与发展轨迹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613246866","title":"Tuhura Biosciences, Inc.盘中异动 早盘快速上涨8.18%报1.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613246866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613246866?lang=zh_cn&edition=full","pubTime":"2026-02-20 22:31","pubTimestamp":1771597903,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日22时31分，Tuhura Biosciences, Inc.股票出现异动，股价大幅上涨8.18%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220223143a70d9787&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612925624","title":"Tuhura Biosciences, Inc.盘中异动 快速下跌5.26%报1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612925624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612925624?lang=zh_cn&edition=full","pubTime":"2026-02-17 23:30","pubTimestamp":1771342229,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日23时30分，Tuhura Biosciences, Inc.股票出现波动，股价大幅跳水5.26%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Polaryx Therapeutics, Inc.、Quoin Pharmaceuticals Ltd、Eyepoint, Inc.涨幅较大，Ernexa Therapeutics Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为75.47%、58.89%、50.22%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Polaryx Therapeutics, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为27.14%、26.97%、25.79%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021723302995415b89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159427520","title":"TuHURA提交TBS-2025治疗血液类癌症的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1159427520","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159427520?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:50","pubTimestamp":1771332610,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. 已正式向监管机构递交了其候选药物TBS-2025的研究性新药申请，该药物旨在针对血液相关癌症开展临床治疗研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186309065","title":"TuHURA生物科学公司计划于2026年第二季度启动针对NPM1突变型复发/难治性急性髓系白血病的二期研究，初步一期结果将于2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1186309065","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186309065?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:48","pubTimestamp":1771332495,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司近日披露其研发管线的最新进展。该公司计划于2026年第二季度正式启动针对NPM1突变型复发/难治性急性髓系白血病的二期临床研究。这项研究旨在评估其在研疗法对该特定患者群体的安全性与有效性。\n与此同时，该药物一期临床研究的初步数据预计将于2026年第三季度揭晓。这些早期结果将为后续临床开发提供重要依据，并有助于优化二期试验的设计方案。公司表示，将严格遵循监管要求推进研究进程，力求为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608977807","title":"Tuhura Biosciences, Inc.盘中异动 快速下挫5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608977807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608977807?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:33","pubTimestamp":1770129200,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日22时33分，Tuhura Biosciences, Inc.股票出现波动，股价快速跳水5.55%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。该公司的个性化癌症候选疫苗 IFx-2.0 旨在克服对检查点抑制剂的主要耐药性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020322332197a4b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169978766","title":"TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169978766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169978766?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:45","pubTimestamp":1770036316,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布，其研发的候选药物IFX-2.0已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，适应症为IIb期至IV期皮肤黑色素瘤。\n孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面，有望在药物开发及后续商业化进程中享受一系列政策支持，包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。\n此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601937463","title":"Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601937463?lang=zh_cn&edition=full","pubTime":"2026-01-08 04:02","pubTimestamp":1767816142,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日04时02分，Tuhura Biosciences, Inc.股票出现异动，股价急速上涨6.74%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为3.15%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Erasca, Inc.涨幅较大，Cardio Diagnostics Holdings Inc.、Pmgc Holdings Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1093.70%、682.96%、351.70%，振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Erasca, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为202.13%、67.49%、50.85%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":0.201},{"period":"3month","weight":0.6},{"period":"6month","weight":2.1589},{"period":"1year","weight":-0.0484},{"period":"ytd","weight":2.1188}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司，成立于2009年6月24日，名称为Berry Only，Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法，以降低风险，满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤（GBM）和REM-001治疗皮肤转移性乳腺癌（CMBC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.054973},{"month":2,"riseRate":0.2,"avgChangeRate":0.076571},{"month":3,"riseRate":0.4,"avgChangeRate":0.006899},{"month":4,"riseRate":0.4,"avgChangeRate":-0.002636},{"month":5,"riseRate":0.6,"avgChangeRate":1.079221},{"month":6,"riseRate":0.5,"avgChangeRate":-0.03295},{"month":7,"riseRate":0.5,"avgChangeRate":-0.012348},{"month":8,"riseRate":0.5,"avgChangeRate":-0.086193},{"month":9,"riseRate":0.3,"avgChangeRate":-0.103258},{"month":10,"riseRate":0.4,"avgChangeRate":-0.116072},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.220735}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}